NCT04987073 Vitamin D Analog in Vitamin D 24-hydroxylase Deficiency
| NCT ID | NCT04987073 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Caen |
| Condition | Idiopathic Infantile Hypercalcemia - Severe Form |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2022-07-17 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2022-07-17 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Preclinical evaluation of a vitamin D analog for the treatment of vitamin D 24-hydroxylase using fibroblast from patients with CYP24A1 mutation.
Eligibility Criteria
Inclusion Criteria: * biallelic mutation in CYP24A1 * consent Exclusion Criteria: * none
Frequently Asked Questions
Who can join the NCT04987073 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Idiopathic Infantile Hypercalcemia - Severe Form. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04987073 currently recruiting?
Yes, NCT04987073 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Hospital, Caen to inquire about joining.
Where is the NCT04987073 trial being conducted?
This trial is being conducted at Caen, France.
Who is sponsoring the NCT04987073 clinical trial?
NCT04987073 is sponsored by University Hospital, Caen. The trial plans to enroll 30 participants.